<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26312707</article-id>
      <article-id pub-id-type="pmc">4540541</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20153538</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Use of tumor necrosis factor alpha (TNF &#x3B1;) antagonists in a
patient with psoriasis and Chagas disease<xref ref-type="fn" rid="fn01">*</xref></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Navarrete-Dechent</surname>
            <given-names>Cristi&#xE1;n</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Majerson</surname>
            <given-names>Daniela</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Torres</surname>
            <given-names>Marisa</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Armijo</surname>
            <given-names>Daniela</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Patel</surname>
            <given-names>Mahir</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Menter</surname>
            <given-names>Alan</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de la Cruz</surname>
            <given-names>Claudia</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="aff" rid="aff03">3</xref>
        </contrib>
      </contrib-group>
      <aff id="aff01"><label>1</label>Pontificia Universidad Cat&#xF3;lica de Chile - Santiago,
Chile.</aff>
      <aff id="aff02"><label>2</label>University Medical Center - Dallas (TX), United
States.</aff>
      <aff id="aff03"><label>3</label>Clinica Dermacross, Santiago, Chile.</aff>
      <author-notes>
        <corresp id="c01">MAILING ADDRESS: Claudia de la Cruz. Cl&#xED;nica Dermacross. Av. Manquehue
Norte 2051C. Vitacura, Santiago, Chile. E-mail:
<email>ccruzf@gmail.com</email></corresp>
        <fn fn-type="conflict">
          <p>Conflict of Interest: None.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>May-Jun</season>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>May-Jun</season>
        <year>2015</year>
      </pub-date>
      <volume>90</volume>
      <issue>3 Suppl 1</issue>
      <fpage>171</fpage>
      <lpage>174</lpage>
      <history>
        <date date-type="received">
          <day>18</day>
          <month>3</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>28</day>
          <month>5</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2015 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>There are several studies on the benefits of using TNF&#x3B1; antagonists in the
treatment of psoriasis, but few studies addressing the interaction of these drugs
with chronic infections. We report the case of a 52-year-old patient diagnosed with
psoriasis refractory to traditional systemic agents, who was treated with biologic
therapies. After one year of treatment with biologic agents, the patient was
diagnosed with Chagas Disease.</p>
      </abstract>
      <kwd-group>
        <kwd>Biological agents</kwd>
        <kwd>Chagas disease</kwd>
        <kwd>Psoriasis</kwd>
        <kwd>Tumor necrosis factor-alpha</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Long-term safety data on the use of TNF-&#x3B1; antagonists in psoriasis, as well as
their interaction with concurrent comorbidities are still to be properly evaluated.
TNF-&#x3B1; agents have been associated with increased risk of serious infections and
reactivation of tuberculosis.<sup><xref rid="r01" ref-type="bibr">1</xref></sup>
Increased incidence of opportunistic infections such as cerebral toxoplasmosis and
toxoplasmic chorioretinitis have also been reported secondary to the use of
Infliximab.<sup><xref rid="r02" ref-type="bibr">2</xref></sup> Interactions with
chronic infectious illnesses such as Chagas disease (CD) have not been previously
assessed.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>A 52-year-old man from a rural-zone in northern Chile sought our clinic in December 2007
with a diagnosis of psoriasis established when he was 14-yearsold. He had over 80% of
cutaneous involvement (PASI 20.6, (<xref ref-type="fig" rid="f01">Figure 1</xref>). He
had been treated with methotrexate, PUVA and acitretin with limited response. Chest
radiography and PPD test were both within normal limits and we decided to start
Etanercept 25 mg twice a week, subsequently titrated to 50 mg achieving only partial
response. After five months, the patient was switched to adalimumab with significant
improvement.</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>A: Patient before treatment with adalimumab. B: after treatment with
adalimumab</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0171-g01"/>
      </fig>
      <p>Additionally, he referred a 5-year history of progressive constipation with poor
response to laxatives. In August 2009 he underwent surgery due to megacolon (<xref ref-type="fig" rid="f02">Figure 2</xref>). Histology was consistent with chagasic
megacolon. The patient had not been previously diagnosed with Chagas disease (CD), but
he most likely had it since childhood. Biologic therapy was subsequently discontinued
while the extent of CD was assessed.</p>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>Abdominal X-ray examination with Barium enema. Note the dilatation of the sigmoid
colon</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0171-g02"/>
      </fig>
      <p>Indirect immunofluorescence (IIF) IgG, qualitative polymerase chain reaction (qPCR), and
real-time polymerase chain reaction (rtPCR, <xref ref-type="table" rid="t01">Chart
1</xref>) were performed in order to investigate <italic>Trypanosoma cruzi</italic>.
Esophageal involvement was evaluated with barium swallow and cardiac involvement was
explored with electrocardiogram and echocardiogram, all of which were normal. Specific
therapy for CD was initiated with 5-nitrofuran 5 mg/kg/day and increased to 7 mg/kg/day
for a 60-day-regimen on two occasions (August 2009 and May 2010 due to an alteration in
the parasitemia dynamics).</p>
      <table-wrap id="t01" orientation="portrait" position="float">
        <label>CHART 1</label>
        <caption>
          <p>Parasitological study and follow-up of the patient</p>
        </caption>
        <table frame="box" rules="groups">
          <tbody>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
              <td align="left" rowspan="1" colspan="1"><bold>Antibody studies</bold>&#xA0;</td>
              <td align="left" rowspan="1" colspan="1"><bold>Parasitemia studies</bold>&#xA0;</td>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">DATE</td>
              <td align="left" rowspan="1" colspan="1"><bold>IIF T cruzi</bold>&#xA0;</td>
              <td align="left" rowspan="1" colspan="1"><bold>Qualitative PCR</bold>&#xA0;</td>
              <td align="left" rowspan="1" colspan="1"><bold><italic>Quantitative PCR</italic></bold>&#xA0;</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
              <td align="left" rowspan="1" colspan="1"><bold><italic>T cruzi (PUC)</italic></bold>&#xA0;</td>
              <td align="left" rowspan="1" colspan="1"><bold><italic>T cruzi (ISP)</italic></bold>&#xA0;</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">08/2009</td>
              <td align="left" rowspan="1" colspan="1">Positive 1/20</td>
              <td align="left" rowspan="1" colspan="1">Negative</td>
              <td align="left" rowspan="1" colspan="1">-</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">04/2010</td>
              <td align="left" rowspan="1" colspan="1">Positive 1/20</td>
              <td align="left" rowspan="1" colspan="1">Negative</td>
              <td align="left" rowspan="1" colspan="1">-</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">05/2010</td>
              <td align="left" rowspan="1" colspan="1">Positive 1/20</td>
              <td align="left" rowspan="1" colspan="1">Positive</td>
              <td align="left" rowspan="1" colspan="1">Positive</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
              <td align="left" rowspan="1" colspan="1">Real time PCR: Quantification:<bold> 3000 DNA</bold><bold>
copies/ul.</bold>&#xA0;</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">12/2010</td>
              <td align="left" rowspan="1" colspan="1">Positive 1/20</td>
              <td align="left" rowspan="1" colspan="1">Negative</td>
              <td align="left" rowspan="1" colspan="1">Negative</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">05/2011</td>
              <td align="left" rowspan="1" colspan="1">Positive 1/20</td>
              <td align="left" rowspan="1" colspan="1">Negative</td>
              <td align="left" rowspan="1" colspan="1">Negative</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="TFN01">
            <p>Captions: IIF: indirect immunofluorescence; PCR: polymerase chain reaction;
PUC: Pontificia Universidad Cat&#xF3;lica de Chile; ISP: Instituto de Salud P&#xFA;blica
de Chile</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>Meanwhile, the patient's psoriatic lesions recurred, dramatically affecting his quality
of life. The patient requested to have biologic therapy restarted. Potential adverse
effects were carefully explained and discussed with him.</p>
      <p>The patient was prescribed adalimumab 40 mg twice a month with excellent response (PASI
2.1, <xref ref-type="fig" rid="f01">Figure 1</xref>) without evidence of CD reactivation
as indicated by a non-reactive rtPCR after one-year follow-up.</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p><italic>Trypanosoma cruzi</italic> infection is a vectorial parasitic zoonosis caused by
a hemoflagellate organism.<sup><xref rid="r03" ref-type="bibr">3</xref></sup> The
infection, known to be highly burdensome, is classified as a Neglected Tropical Disease
that affects people in extreme poverty and helps to perpetuate their
impoverishment.<sup><xref rid="r04" ref-type="bibr">4</xref></sup></p>
      <p>Twenty-percent of Latin American inhabitants (109 million individuals) are at risk of
acquiring the infection, with 7.7 million individuals infected in 2005.<sup><xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r05" ref-type="bibr">5</xref>,<xref rid="r06" ref-type="bibr">6</xref></sup> In Chile, there isn't enough information
on the disease, however 0.4 - 0.7% of blood donors test positive for <italic>T.
cruzi.</italic><sup><xref rid="r07" ref-type="bibr">7</xref></sup></p>
      <p>With the advent of traveling and migration, the disease is not only restricted to
endemic areas but it is spread worldwide, making the knowledge on CD mandatory to all
physicians and not only those living in the Americas. <sup><xref rid="r03" ref-type="bibr">3</xref></sup></p>
      <p>The effects of immunomodulatory drugs on <italic>T. cruzi</italic> parasitemia dynamics
and CD course in humans are not known, with only experimental evidence available from
animal models with contradictory results.<sup><xref rid="r08" ref-type="bibr">8</xref>-<xref rid="r10" ref-type="bibr">10</xref></sup> Some studies
demonstrated myocardial tissue alteration in Chagasic hamsters, with decrease in left
ventricular systolic function, increase in IL-10-mRNA expression and an increase in the
subendocardium inflammatory foci.<sup><xref rid="r08" ref-type="bibr">8</xref></sup>
Other reports have shown even a decrease in the myocardial inflammatory foci and
myocarditis in animals treated with TNF&#x3B1; antagonists and a down regulation of
CD4<sup>+</sup> and CD8<sup>+</sup> T cells in cardiac tissue, keeping the expression
of normal cardiac proteins like connexin-43, which is reduced and disorganized in
untreated infected mice.<sup><xref rid="r09" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref></sup> The most likely explanation is that
TNF&#x3B1; in CD may act as a pro-inflammatory cytokine, inducing target-organ damage
secondary to the recruitment and chemotaxis of neutrophils, lymphocytes and macrophages,
thereby maintaining tissue inflammation.<sup><xref rid="r08" ref-type="bibr">8</xref>-<xref rid="r10" ref-type="bibr">10</xref></sup></p>
      <p>Conversely, TNF&#x3B1; may aid in containing <italic>T. cruzi</italic> infection and
thus help maintaining low serologic levels of the hemoflagellate organism, leading to a
complex interaction between the host and the agent. <italic>T. cruzi</italic>
parasitemia did not change subsequent to anti-TNF administration in any of these
studies.<sup><xref rid="r08" ref-type="bibr">8</xref>-<xref rid="r10" ref-type="bibr">10</xref></sup> Similarly, strict follow-up with rtPCR studies did not
show any evidence of reactivation of CD with the use of etanercept or adalimumab in our
patient. The detection of 1000 copies of <italic>T.cruzi</italic> DNA in the rtP-CR
performed in May 2010 represents a very low level and could be explained by the natural
fluctuation of <italic>T. cruzi</italic> parasitemia (or <italic>parasitemia
dynamics</italic>) <sup><xref rid="r11" ref-type="bibr">11</xref></sup> since this
change occurred while the patient was off biologic therapies. This alteration in
parasitemia responded well to an additional course of 5-nitrofuran, and the rtPCRs
performed in December 2010 and May 2011 were negative for <italic>T.cruzi</italic> DNA
despite the patient being on anti-TNF therapy since May 2010.</p>
      <p>The possibility that Chagas megacolon was triggered in our patient by our initial
TNF&#x3B1;-antagonist therapy seems very unlikely, as the mean time of development of
this chronic complication is namely 20 - 30 years.</p>
      <p>Anti-TNF drugs' safety profiles and their use in patients with chronic infections such
as CD are still undergoing long-term evaluation. This issue is of particular concern
given the increasing prevalence of biologic therapy for multiple inflammatory disorders
worldwide and the potential for their use in patients with unknown concurrent chronic
infections such as CD.<sup><xref rid="r03" ref-type="bibr">3</xref></sup></p>
      <p>Screening recommendations for certain chronic infections prior to biologic therapy
initiation have already been published and they include testing for hepatitis and
tuberculosis at baseline.<sup><xref rid="r01" ref-type="bibr">1</xref></sup> Screening
for additional infectious diseases are not included in these guidelines.</p>
      <p>Lassoued <italic>et al</italic> postulated performing <italic>Toxoplasma</italic>
serology as an initial workup, prior to the starting of anti-TNF&#x3B1;
therapy.<sup><xref rid="r02" ref-type="bibr">2</xref></sup> Screening for
hepatitis B virus is also part of the initial workup due to known cases of HBV
reactivation and even death secondary to anti-TNF therapy.<sup><xref rid="r12" ref-type="bibr">12</xref></sup></p>
      <p>Furthermore, we suggest adding CD serology to initial screening studies<sup><xref rid="r01" ref-type="bibr">1</xref></sup> before starting biologic therapies in CD
endemic areas. This would allow a full treatment course with 5-nitrofuran prior to
anti-TNF therapy, similar to concurrent HBV infection or TB infection. It would reduce
and prevent an unknown but potential risk of CD reactivation, as occurs in 20% of HIV
patients with severe meningoencephalitis, myocarditis, high parasitemia levels and even
death (work up is listed in <xref ref-type="table" rid="t02">chart 2</xref>).<sup><xref rid="r13" ref-type="bibr">13</xref>,<xref rid="r14" ref-type="bibr">14</xref></sup></p>
      <table-wrap id="t02" orientation="portrait" position="float">
        <label>CHART 2</label>
        <caption>
          <p>Suggested work-up for patients in endemic areas (or who are traveling/ have
traveled to them) planning to start biologic therapies. Treatment could be
performed with Nifurtimox or Benzimidazole but not with both. Captions: IIF:
indirect immunofluorescence</p>
        </caption>
        <table frame="box" rules="groups">
          <tbody>
            <tr>
              <td align="left" rowspan="1" colspan="1"><bold>Step 1: Serologic screening</bold>&#xA0;</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">IIF IgG T. cruzi (qualitative serology)</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Seropositive patients go to Step 2.</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1"><bold>Step 2: Enter Chagas disease protocol -
Therapy</bold>&#xA0;</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Evaluation of organ involvement (heart, esophagus, colon)</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Symptomatic therapy according to clinical data.</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Go to Step 3.</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1"><bold>Step 3: Quantitative polymerase chain reaction (PCR) to
T cruzi (not qualitative)</bold>&#xA0;</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Specific anti-parasitic therapy.</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1"><bold>Step 4: Clinical-serological control</bold>&#xA0;</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">IIF IgG T. cruzi and quantitative PCR T. cruzi</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Lifetime follow-up.</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>Recently, <italic>T. cruzi</italic> serology was added as a screening tool in all
patients who are candidates to solid organ transplants (unpublished data, observation of
MT).</p>
      <p>A consensus on guidelines for biologic therapy in the presence of CD has yet to be
established and it would aid physicians in the initial workup of patients, in order to
offer the highest safety and risk-benefit profiles to patients.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="supported-by">
        <p>Financial Support: None.</p>
      </fn>
      <fn fn-type="other">
        <p><bold>How to cite this article:</bold> Navarrete-Dechent C, Majerson D, Torres M,
Armijo D, Patel M, Menter A, de la Cruz C. Use of tumor necrosis factor alpha
(TNF&#x3B1;) antagonists in a patient with psoriasis and Chagas disease. An Bras
Dermatol. 2015;90(3 Supl 1):S171-4.</p>
      </fn>
      <fn fn-type="other" id="fn01">
        <label>*</label>
        <p>Work performed at the Department of Dermatology, Facultad de Medicina, Pontificia
Universidad Cat&#xF3;lica de Chile - Santiago, Chile.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Menter</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gottlieb</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Van Voorhees</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Leonardi</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>KB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Guidelines of care for the management of psoriasis and psoriatic
arthritis: Section 1. Overview of psoriasis and guidelines of care for the
treatment of psoriasis with biologics</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2008</year>
          <volume>58</volume>
          <fpage>826</fpage>
          <lpage>850</lpage>
          <pub-id pub-id-type="pmid">18423260</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lassoued</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Zabraniecki</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Marin</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Billey</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Toxoplasmic chorioretinitis and antitumor necrosis factor treatment in
rheumatoid arthritis</article-title>
          <source>Semin Arthritis Rheum</source>
          <year>2007</year>
          <volume>36</volume>
          <fpage>262</fpage>
          <lpage>263</lpage>
          <pub-id pub-id-type="pmid">17067660</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rassi</surname>
              <given-names>A</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Rassi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Marin-Neto</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Chagas disease</article-title>
          <source>Lancet</source>
          <year>2010</year>
          <volume>375</volume>
          <fpage>1388</fpage>
          <lpage>1402</lpage>
          <pub-id pub-id-type="pmid">20399979</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hotez</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Fenwick</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Savioli</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Molyneux</surname>
              <given-names>DH</given-names>
            </name>
          </person-group>
          <article-title>Rescuing the bottom billion through control of neglected tropical
diseases</article-title>
          <source>Lancet</source>
          <year>2009</year>
          <volume>373</volume>
          <fpage>1570</fpage>
          <lpage>1575</lpage>
          <pub-id pub-id-type="pmid">19410718</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aguilar V</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Abad-Franch</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Racines</surname>
              <given-names>VJ</given-names>
            </name>
            <name>
              <surname>Paucar</surname>
              <given-names>CA</given-names>
            </name>
          </person-group>
          <article-title>Epidemiology of Chagas disease in Ecuador. A brief
review</article-title>
          <source>Mem Inst Oswaldo Cruz</source>
          <year>1999</year>
          <volume>94</volume>
          <fpage>387</fpage>
          <lpage>393</lpage>
          <pub-id pub-id-type="pmid">10677762</pub-id>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <collab>Organizaci&#xF3;n Panamericana de la Salud</collab>
          </person-group>
          <source>Estimaci&#xF3;n cuantitativa de la enfermedad de Chagas en las Am&#xE9;ricas</source>
          <publisher-loc>Montevideo, Uruguay</publisher-loc>
          <publisher-name>Organizaci&#xF3;n Panamericana de la Salud</publisher-name>
          <year>2006</year>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <article-title>Guidelines for Chagas disease. 2006. Part I. Introduction and
epidemiology</article-title>
          <source>Rev Chilena Infectol</source>
          <year>2008</year>
          <volume>25</volume>
          <fpage>189</fpage>
          <lpage>193</lpage>
          <pub-id pub-id-type="pmid">18580996</pub-id>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bilate</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Salemi</surname>
              <given-names>VM</given-names>
            </name>
            <name>
              <surname>Ramires</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>de Brito</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Russo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fonseca</surname>
              <given-names>SG</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>TNF blockade aggravates experimental chronic Chagas disease
cardiomyopathy</article-title>
          <source>Microbes Infect</source>
          <year>2007</year>
          <volume>9</volume>
          <fpage>1104</fpage>
          <lpage>1113</lpage>
          <pub-id pub-id-type="pmid">17644389</pub-id>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kroll-Palhares</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Silv&#xE9;rio</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Michailowsky</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Marino</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>NM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>TNF/TNFR1 signaling up-regulates CCR5 expression by CD8+ T lymphocytes
and promotes heart tissue damage during Trypanosoma cruzi infection: beneficial
effects of TNF-a blockade</article-title>
          <source>Mem Inst Oswaldo Cruz</source>
          <year>2008</year>
          <volume>103</volume>
          <fpage>375</fpage>
          <lpage>385</lpage>
          <pub-id pub-id-type="pmid">18660993</pub-id>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>P&#xE9;rez</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Fontanella</surname>
              <given-names>GH</given-names>
            </name>
            <name>
              <surname>Nocito</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Revelli</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bottasso</surname>
              <given-names>OA</given-names>
            </name>
          </person-group>
          <article-title>Short treatment with the tumour necrosis factor-alpha blocker
infliximab diminishes chronic chagasic myocarditis in rats without evidence of
Trypanosoma cruzi reactivation</article-title>
          <source>Clin Exp Immunol</source>
          <year>2009</year>
          <volume>157</volume>
          <fpage>291</fpage>
          <lpage>299</lpage>
          <pub-id pub-id-type="pmid">19604269</pub-id>
        </element-citation>
      </ref>
      <ref id="r11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bua</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Volta</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Perrone</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Scollo</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Vel&#xE1;zquez</surname>
              <given-names>EB</given-names>
            </name>
            <name>
              <surname>Ruiz</surname>
              <given-names>AM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>How to improve the early diagnosis of Trypanosoma cruzi infection:
relationship between validated conventional diagnosis and quantitative DNA
amplification in congenitally infected children</article-title>
          <source>PLoS Negl Trop Dis</source>
          <year>2013</year>
          <volume>7</volume>
          <elocation-id/>
        </element-citation>
      </ref>
      <ref id="r12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ramos-Casals</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Therapy: Are TNF blockers safe for patients with hepatitis B virus
infection?</article-title>
          <source>Nat Rev Rheumatol</source>
          <year>2010</year>
          <volume>6</volume>
          <fpage>618</fpage>
          <lpage>620</lpage>
          <pub-id pub-id-type="pmid">21037559</pub-id>
        </element-citation>
      </ref>
      <ref id="r13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ferreira</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Nishioka Sde</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Silvestre</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Borges</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Nunes-Ara&#xFA;jo</surname>
              <given-names>FR</given-names>
            </name>
            <name>
              <surname>Rocha</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Reactivation of Chagas' disease in patients with AIDS: report of three
new cases and review of the literature</article-title>
          <source>Clin Infect Dis</source>
          <year>1997</year>
          <volume>25</volume>
          <fpage>1397</fpage>
          <lpage>1400</lpage>
          <pub-id pub-id-type="pmid">9431385</pub-id>
        </element-citation>
      </ref>
      <ref id="r14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Freitas</surname>
              <given-names>VL</given-names>
            </name>
            <name>
              <surname>da Silva</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Sartori</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Bezerra</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Westphalen</surname>
              <given-names>EV</given-names>
            </name>
            <name>
              <surname>Molina</surname>
              <given-names>TD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Real-time PCR in HIV/Trypanosoma cruzi coinfection with and without
Chagas disease reactivation: association with HIV viral load and CD4
level</article-title>
          <source>PLoS Negl Trop Dis</source>
          <year>2011</year>
          <volume>5</volume>
          <elocation-id/>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
